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Pneumocystis pneumonia (PCP) remains a major
cause of illness and death in HIV-infected persons. Sulfa
drugs, trimethoprim-sulfamethoxazole (TMP-SMX), and
dapsone are mainstays of PCP treatment and prophylaxis.
While prophylaxis has reduced the incidence of PCP, its
use has raised concerns about development of resistant
organisms. The inability to culture human Pneumocystis,
Pneumocystis jirovecii, in a standardized culture system
prevents routine susceptibility testing and detection of drug
resistance. In other microorganisms, sulfa drug resistance
has resulted from specific point mutations in the dihy-
dropteroate synthase (DHPS) gene. Similar mutations
have been observed in P. jirovecii. Studies have consistent-
ly demonstrated a significant association between the use
of sulfa drugs for PCP prophylaxis and DHPS gene muta-
tions. Whether these mutations confer resistance to TMP-
SMX or dapsone plus trimethoprim for PCP treatment
remains unclear. We review studies of DHPS mutations in
P. jirovecii and summarize the evidence for resistance to
sulfamethoxazole and dapsone. 
Although decreasing in incidence as a result of combi-nation antiretroviral therapy and effective prophylax-
is, Pneumocystis pneumonia (PCP), caused by
Pneumocystis jirovecii (formerly P. carinii f. sp. hominis),
remains the most common AIDS-defining opportunistic
infection, as well as the most frequent serious opportunis-
tic infection in HIV-infected persons, in the United States
and Europe. Despite the fact that this infection can be pre-
vented, certain patients continue to be at increased risk for
PCP. Specifically, PCP frequently signals HIV infection in
patients not previously known to be HIV-infected (1).
Patients who are not receiving regular medical care, as
well as those who are not receiving or responding to anti-
retroviral therapy or prophylaxis, are also at increased risk
for PCP (2). PCP may also develop in other immunosup-
pressed populations, such as cancer patients and transplant
recipients. Furthermore, PCP remains a leading cause of
death among critically ill patients, despite advances in
treatment and management (3).
The first-line treatment and prophylaxis regimen for
PCP is trimethoprim-sulfamethoxazole (TMP-SMX) (4).
While prophylaxis has been shown to reduce the incidence
of PCP, the widespread and long-term use of TMP-SMX in
HIV patients has raised concerns regarding the develop-
ment of resistant organisms. Even short-term exposure to
TMP-SMX can be associated with the emergence of TMP-
SMX resistance, as has been demonstrated in patients with
acute cystitis caused by Escherichia coli (5). Indeed, an
increased number of sulfa-resistant bacteria have been iso-
lated in HIV patients, which coincides with the rise in
TMP-SMX prophylaxis for PCP (6,7). In one study, the
prevalence of TMP-SMX–resistant Staphylococcus aureus
and Enterobacteriaceae species isolated in all hospitalized
patients increased significantly from <5.5% of isolates
before 1986 to 20% in 1995, during which time TMP-
SMX prophylaxis was increasing in HIV-infected patients
(6). In addition, the rise in resistant organisms was signif-
icantly more prominent in samples obtained from HIV-
infected patients, in whom resistant isolates increased from
6.3% in 1988 to 53% in 1995. Another study found that
significantly more TMP-SMX–resistant organisms were
isolated from HIV-infected patients who had received
TMP-SMX than from patients who had not received TMP-
SMX (7). 
Given the emergence of resistance to TMP-SMX
among many bacteria (8), concern has focused on the
potential development of resistant Pneumocystis. Based
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on animal studies, nearly all of the anti-Pneumocystis
activity of TMP-SMX is due to sulfamethoxazole (9). The
development of sulfonamide resistance could result in the
failure of sulfamethoxazole as well as dapsone, a sulfone
antimicrobial agent also used in the treatment and prophy-
laxis of PCP. While separate lines of investigation also
suggest that Pneumocystis may be developing resistance
to atovaquone, a second-line PCP treatment and prophy-
laxis regimen (10), we concentrate our review on the evi-
dence for the development of sulfonamide-resistant
Pneumocystis.
Mechanisms of Sulfonamide Resistance
Sulfonamides act by interfering with folate synthesis.
Since many microorganisms cannot transport folate into
cells as mammalian cells can, most prokaryotes and lower
eukaryotes must synthesize folates de novo (11).
Sulfonamides inhibit one of the integral enzymes in folate
synthesis, dihydropteroate synthase (DHPS), which cat-
alyzes the condensation of para-aminobenzoic acid and
pteridine to form dihydropteroic acid (Figure). Since mam-
malian cells lack DHPS, sulfonamides can selectively
inhibit the growth of various microorganisms.
Trimethoprim, part of the fixed combination TMP-SMX,
inhibits another of the integral enzymes, the dihydrofolate
reductase (DHFR).
Resistance to sulfonamides can emerge by means of a
number of mechanisms (12). In most gram-negative
enteric bacteria, sulfonamide resistance is largely plasmid-
borne and related to drug-resistant DHPS variants with
substantial sequence divergence (12). Chromosomal muta-
tions in the DHPS locus—such as point mutations, inser-
tions of duplicate amino acids, or larger sequence alter-
ations as a result of recombination—can also lead to resist-
ance (8). In some organisms, several different mechanisms
of resistance have been identified in different strains. For
example, some strains of Neisseria meningitidis have
acquired a DHPS gene with 10% sequence divergence,
postulated by others to be due to recombination (12),
whereas other Neisseria strains have acquired a chromoso-
mal insertion, resulting in the addition of two amino acids
to DHPS (13). In other organisms, such as E. coli and
Plasmodium falciparum, nonsynonymous point mutations
resulting in amino acid substitutions in DHPS can confer
sulfa resistance (14,15). Furthermore, the accumulation of
additional mutations over time can confer increasing levels
of sulfa resistance, as has occurred in P. falciparum (16).
Dihydropteroate Synthase Mutations 
in Pneumocystis
Similar to other microorganisms, mutations have been
identified in the DHPS gene of Pneumocystis jirovecii,
which has raised the question of whether P. jirovecii is
developing resistance to sulfonamides. The DHPS gene of
P. jirovecii has been sequenced and is part of the folic acid
synthesis gene or fas gene; it encodes a trifunctional pro-
tein along with dihydroneopterin aldolase and hydrox-
ymethyldihydropterin pyrophosphokinase (17). Sulfa
medications appear to exert selective pressure on
Pneumocystis (18), as the DHPS gene is more likely to dis-
play mutations in highly conserved regions in patients with
PCP who have previously been exposed to sulfa medica-
tions (19–25). These DHPS gene mutations were rarely
found in clinical isolates before the early 1990s (19,20,22).
Genetic analysis suggests that the mutations arose inde-
pendently in multiple strains of Pneumocystis, which sup-
ports the theory that exposure to sulfa medications selects
for DHPS gene mutations (26). Furthermore, DHPS gene
mutations have not been found in other mammalian
Pneumocystis species that have not been exposed to sulfa
medications (18,27).
Several factors suggest that the mutations observed in
P. jirovecii may confer resistance to sulfa medications. The
region of the DHPS gene in which mutations have been
identified is one that is highly conserved among other
organisms, including Plasmodium falciparum,
Streptococcus pneumoniae, E. coli, and Bacillus subtilis
(18). The most common mutations identified in the
Pneumocystis jirovecii DHPS are nonsynonymous point
mutations, which result in amino acid substitutions at posi-
tions 55, 57, or both. Different strains with single or dou-
ble amino acid substitutions at these positions have been
identified (Table 1). Based on homology to the E. coli
DHPS, these point mutations appear to be in an active site
of the enzyme involved in substrate binding; thus, amino
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Figure. Inhibition of folate synthesis by sulfonamides and trimetho-
prim. PABA, paraaminobenzoic acid; DHPS, dihydropteroate syn-
thase; DHFR, dihydrofolate reductase. 
acid substitutions in these regions could result in structur-
al changes that could interfere with substrate binding and
enzyme activity (21). Likewise, similar point mutations in
positions equivalent to this site in Plasmodium falciparum
(15) and Mycobacterium leprae (28) confer sulfa resist-
ance. Other mutations near this site also cause sulfa resist-
ance in S. pneumoniae and P. falciparum (18).
However, the inability to reliably culture Pneumocystis
jirovecii in a standardized in vitro culture system prevents
the routine susceptibility testing of Pneumocystis. The lack
of a standardized culture system also hampers research
into the development and testing of new antimicrobial
agents with anti-Pneumocystis activity, which highlights
our reliance on TMP-SMX as the current mainstay of ther-
apy. Thus, the clinical significance of these DHPS gene
mutations must be inferred from correlating the clinical
outcome with the presence of DHPS gene mutations in
patients with PCP.
Association of Sulfamethoxazole and Dapsone
with DHPS Gene Mutations
Several studies have consistently demonstrated a sig-
nificant association between the use of TMP-SMX or dap-
sone for PCP prophylaxis in HIV-infected persons and the
presence of DHPS gene mutations (Table 2) (19–25,29).
One study extended these findings to the use of
pyrimethamine plus sulfadoxine for PCP prophylaxis (30).
Another study demonstrated an apparent reversal of the
DHPS mutant-to-wild-type ratios after the use of TMP-
SMX was restricted (31). In total, studies report >700
episodes of PCP, span a period from 1976 to 2001, and
include patient data and clinical specimens from multiple
cities in several different countries. Unfortunately, these
studies used different criteria to define PCP prophylaxis
with TMP-SMX or dapsone, which effectively limits
attempts at data pooling for more direct and detailed analy-
ses. In addition, most of the studies collected data by
abstracting information from patient charts. Thus, these
studies were unable to assess whether patients adhered to
the prescribed prophylaxis. Nevertheless, seven of the nine
studies found that most HIV-infected patients with a diag-
nosis of PCP who had been prescribed TMP-SMX or dap-
sone for PCP prophylaxis had Pneumocystis that contained
DHPS mutations (range 19%–80%, Table 2) (19–24,30).
Furthermore, eight of the nine studies reported that PCP
patients for whom TMP-SMX or dapsone was prescribed
were more likely to have Pneumocystis that contained
DHPS mutations than were patients for whom these med-
ications were not prescribed (19–25,30). 
Of note, in all nine studies, DHPS mutations were
observed in PCP patients who were not currently receiving
TMP-SMX or dapsone. Whether these patients who failed
to meet the defined criteria for TMP-SMX or dapsone pro-
phylaxis had ever received one of these medications for
prophylaxis or had received TMP-SMX for a reason other
than PCP prophylaxis at some point during their lives was
difficult to assess with any degree of confidence.
Nevertheless, most of the studies found that only a minor-
ity of PCP patients who had not been prescribed TMP-
SMX or dapsone for PCP prophylaxis had Pneumocystis
that contained DHPS mutations. The study that reported
the highest proportion (48%) used both chart abstraction
and patient interview as sources of clinical information
regarding PCP prophylaxis (23). This study also used a
broad definition of PCP prophylaxis, including patient
report of TMP-SMX use for prophylaxis at any time in life.
Thus, despite rigorous attempts to document TMP-SMX or
dapsone use for PCP prophylaxis and with the broadest
definition of prophylaxis applied, nearly half of the
patients without TMP-SMX or dapsone use had evidence
of DHPS mutations on their clinical PCP specimen.
Among the 26 patients with a new diagnosis of HIV infec-
tion at the time PCP was diagnosed and who thus had
never received PCP prophylaxis, 14 (54%) had
Pneumocystis that contained DHPS gene mutations. The
specific city of residence was also an independent predic-
tor associated with the risk for Pneumocystis that con-
tained DHPS gene mutations. Patients who lived in San
Francisco were five times more likely, and patients who
lived in Seattle were more than three times as likely to
have mutant DHPS than patients who resided in Atlanta,
even when factors including sulfonamide or dapsone PCP
prophylaxis and prior PCP were controlled for. The pres-
ence of DHPS mutations in patients without prior TMP-
SMX or dapsone use for PCP prophylaxis, the absence of
similar mutations in Pneumocystis isolated from other
mammalian species, and the impact of geography on
DHPS genotype have substantial implications for disease
transmission (i.e., person-to-person transmission) that are
beyond the scope of this review (32–35). 
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Lack of Association of Trimethoprim with 
DHFR Gene Mutations
Trimethoprim inhibits another of the integral enzymes
in folate synthesis, DHFR (Figure). In other microorgan-
isms, point mutations in the DHFR gene are an important
mechanism of drug resistance. This finding has led
researchers to examine the DHFR gene of P. jirovecii to
evaluate whether DHFR mutations contribute to TMP-
SMX resistance. To date, two studies have failed to
demonstrate an association between the use of TMP-SMX
for PCP prophylaxis in HIV-infected persons and the pres-
ence of DHFR gene mutations (21,36). In one study, 36 of
37 specimens (from 35 patients, 26 of whom were HIV-
infected) demonstrated identical DHFR sequences, with a
single specimen showing one synonymous nucleotide
change (21). In the second study, 16 (59%) of 27 speci-
mens (from 27 patients, 19 of whom were HIV-infected)
had DHFR gene mutations, 14 had synonymous changes,
and 2 had nonsynonymous changes (36). Neither of the
two patients whose PCP specimen had nonsynonymous
DHFR changes had prior exposure to DHFR inhibitors, yet
both patients were treated successfully for PCP with TMP-
SMX. In addition, this study aligned the Pneumocystis
DHFR sequences with those of E. coli, Staphylococcus
aureus, Streptococcus pneumoniae, and Plasmodium falci-
parum and reported that the observed nonsynonymous
changes in Pneumocystis DHFR were not in the highly
conserved regions of the enzyme as are the amino acid
substitutions that confer resistance to TMP (or
pyrimethamine) in these other organisms. Thus, the pres-
ence and association of DHPS, but not DHFR, gene muta-
tions with the use of specific PCP prophylaxis regimens
argue strongly both for the importance of SMX and dap-
sone against Pneumocystis and the central role of DHPS
mutations in the potential development of TMP-SMX or
dapsone resistance. 
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Clinical Importance of DHPS Gene 
Mutations in Pneumocystis jirovecii
A number of studies have examined the effect of DHPS
gene mutations on clinical outcomes such as death, death
specifically attributable to PCP, and PCP treatment failure
with TMP-SMX or dapsone plus trimethoprim (Table 3)
(19–22,24,25,37–39). Whether the presence of DHPS gene
mutations confers clinical resistance to TMP-SMX or dap-
sone plus trimethoprim for PCP treatment remains unclear
and requires further study. In a multivariate analysis,
Helweg-Larsen and colleagues found that DHPS muta-
tions were an independent predictor associated with
increased death rates (20). In this study, DHPS mutation
was the strongest predictor of death, and patients who had
Pneumocystis that contained DHPS mutations had a
greater than threefold increased risk for death within 3
months compared to patients with the wild-type DHPS,
after important mortality cofactors such as age, CD4+/cell
count, and arterial oxygen partial pressure (PaO2) were
controlled for. Whether this increased death rate was due to
failure of TMP-SMX for PCP treatment is unclear. In fact,
12 (63%) of 19 PCP patients with Pneumocystis that con-
tained DHPS gene mutations responded to PCP treatment
with TMP-SMX. Kazanjian and co-workers found that the
presence of DHPS mutations was associated with an
increased risk for PCP treatment failure with TMP-SMX or
dapsone plus trimethoprim (22). In univariate analysis,
PCP patients who had Pneumocystis that contained DHPS
gene mutations had a greater than twofold increased risk
for treatment failure with one of these regimens, compared
to patients with the wild-type DHPS. In this study, treat-
ment failure was defined as worsening of clinical features
after 7 days of therapy, failure to improve after 10 days of
therapy, or a change in therapy because the treating physi-
cian perceives failure. Patients who responded clinically to
therapy but who switched therapies because of adverse
effects were considered to have been treated successfully.
Similar to the findings of Helweg-Larsen, most patients
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with Pneumocystis that contained DHPS gene mutations
responded to PCP treatment with TMP-SMX or dapsone
plus trimethoprim. Overall, 15 (71%) of 21 PCP patients
with Pneumocystis that contained DHPS gene mutations
responded to PCP treatment with one of these two regi-
mens. In addition, this study found no association between
the presence of DHPS mutations and death at 4 weeks. In
contrast to these prior two studies, Navin and colleagues
found no association between the presence of DHPS muta-
tions and overall number of deaths at 6 weeks, death attrib-
utable specifically to PCP, or PCP treatment failure (39).
Overall, 16 (17%) of 94 PCP patients with DHPS muta-
tions died compared to 9 (25%) of 36 PCP patients with
wild-type DHPS (p = 0.30). Similarly, seven patients (7%)
with PCP with DHPS mutations died as a result of PCP
compared to four patients (11%) with wild-type DHPS.
Among the 66 patients with PCP with DHPS mutations
who were treated with TMP-SMX, 56 (85%) responded to
this treatment. In this study, patients were classified as
having been successfully treated if they completed a full
course of therapy and responded or if they responded suf-
ficiently to be switched from intravenous to oral therapy
and be discharged. Similar to the Kazanjian study, patients
who responded clinically to therapy but who switched
therapies because of adverse effects were considered to
have been treated successfully. This noted TMP-SMX
response rate was significantly better than the rate for
patients with DHPS mutation who were treated with intra-
venous pentamidine or clindamycin plus primaquine (14
[50%] of 28) and for patients with the wild-type DHPS
who were treated with TMP-SMX (23 [64%] of 36). These
results were similar when the analysis was restricted to
patients who had been treated for at least 7 days with their
initial therapy. Although these three patient groups did not
differ in terms of age, CD4-cell count, serum albumin,
serum lactate dehydrogenase (LDH), or proportion who
required corticosteroids, no multivariate analysis was per-
formed to determine independent predictors associated
with death (or PCP treatment failure). Instead, a series of
stratified analyses were performed and failed to detect any
subsets of PCP patients in whom DHPS mutations were
associated with a worse outcome.
Summary and Future Directions
Whether Pneumocystis DHPS gene mutations confer
clinical resistance to TMP-SMX or dapsone plus trimetho-
prim for PCP treatment remains unclear. Published studies
offer conflicting results. Each study used different defini-
tions for PCP prophylaxis and PCP treatment success or
failure, and each examined patient deaths at different time-
points, with different methods of statistical analysis. These
methodologic differences limit attempts at data pooling for
more direct and detailed analyses. The outcome of HIV-
infected patients with PCP is a complex issue, with multi-
ple factors affecting death, including those related to the
patient (e.g., age), the patient’s overall health status (e.g.,
serum albumin), the underlying HIV/AIDS (e.g., coexist-
ing opportunistic infections or conditions), and, of course,
those specific factors related to PCP (e.g., disease severity,
presence of respiratory failure, need for mechanical venti-
lation, and development of serious complications such as
pneumothorax). In each individual report, the overall num-
ber of patients studied and the subset of patients who had
Pneumocystis that contained DHPS mutations and were
treated with TMP-SMX or dapsone plus trimethoprim
were too small to account for these factors and to detect
small differences in outcome that may be related to drug
resistance. Furthermore, these and future observational
studies that examine DHPS genotype and PCP treatment
outcome are complicated by the absence of validated PCP
clinical treatment guidelines, practice standards, and defi-
nitions of treatment success or failure.
While the declining incidence of PCP in the United
States and Europe, as a result of combinations of antiretro-
viral therapy and PCP prophylaxis, might lessen the enthu-
siasm for continued study of this issue, brief consideration
of a number of factors that warn of a future “perfect storm”
suggests that continued study is important. First, most
HIV-infected persons worldwide reside in sub-Saharan
Africa, Southeast Asia, and Latin America, places where
access to antiretroviral therapy and PCP prophylaxis are
limited. Second, PCP is increasingly being recognized as
an important cause of illness in these regions. In many of
these regions, programs to use TMP-SMX as multioppor-
tunistic infection prophylaxis are being implemented, and
Pneumocystis that contains DHPS mutations can be
expected. Next, the treatment options for PCP in these
regions are often limited to TMP-SMX, since regimens
such as pentamidine, clindamycin plus primaquine, trime-
trexate, and atovaquone are unavailable. The existence of
TMP-SMX–resistant Pneumocystis in these regions, com-
bined with the general absence of invasive diagnostic pro-
cedures (e.g., bronchoscopy that might establish an earlier
diagnosis of PCP when the outcome is better) and inten-
sive care facilities (e.g., mechanical ventilation that might
support patients until PCP treatment can be effective),
stresses the importance of further study (40).
Dr. Huang is supported by the National Institutes of Health
K23 HL072117.
Dr. Huang is an associate professor of medicine at the
University of California San Francisco and an attending physi-
cian in the Department of Medicine at San Francisco General
Hospital. He holds dual appointments in the Positive Health
Program for HIV/AIDS and the Division of Pulmonary and
1726 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 10, October 2004
PERSPECTIVES
Critical Care Medicine at San Francisco General Hospital. His
clinical and research interests are focused on HIV-associated pul-
monary diseases, especially Pneumocystis pneumonia.
References
1. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J,
Lindegren ML, et al. Epidemiology of human immunodeficiency
virus-associated opportunistic infections in the United States in the
era of highly active antiretroviral therapy. Clin Infect Dis.
2000;30(Suppl 1):S5–14.
2. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of
Pneumocystis carinii pneumonia in an era of effective prophylaxis:
the relative contribution of non-adherence and drug failure. AIDS.
2000;14:2559–66.
3. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival
with highly active antiretroviral therapy in HIV-infected patients with
severe Pneumocystis carinii pneumonia. AIDS 2003;17:73–80.
4. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing oppor-
tunistic infections among HIV-infected persons–2002.
Recommendations of the U.S. Public Health Service and the
Infectious Diseases Society of America. MMWR Recomm Rep.
2002;51(RR-8):1–52.
5. Brown PD, Freeman A, Foxman B. Prevalence and predictors of
trimethoprim-sulfamethoxazole resistance among uropathogenic
Escherichia coli isolates in Michigan. Clin Infect Dis.
2002;34:1061–6.
6. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK,
Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resist-
ance in the AIDS era. J Infect Dis. 1999;180:1809–18.
7. Wininger DA, Fass RJ. Impact of trimethoprim-sulfamethoxazole
prophylaxis on etiology and susceptibilities of pathogens causing
human immunodeficiency virus-associated bacteremia. Antimicrob
Agents Chemother. 2002;46:594–7.
8. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin
Infect Dis. 2001;32:1608–14.
9. Walzer PD, Foy J, Steele P, Kim CK, White M, Klein RS, et al.
Activities of antifolate, antiviral, and other drugs in an immunosup-
pressed rat model of Pneumocystis carinii pneumonia. Antimicrob
Agents Chemother. 1992;36:1935–42.
10. Kazanjian P, Armstrong W, Hossler PA, Lee CH, Huang L, Beard CB,
et al. Pneumocystis carinii cytochrome b mutations are associated
with atovaquone exposure in patients with AIDS. J Infect Dis.
2001;183:819–22.
11. Skold O. Sulfonamide resistance: mechanisms and trends. Drug
Resistance Updates. 2000;3:155–60.
12. Huovinen P, Sundstrom L, Swedberg G, Skold O. Trimethoprim and
sulfonamide resistance. Antimicrob Agents Chemother.
1995;39:279–89.
13. Qvarnstrom Y, Swedberg G. Additive effects of a two-amino-acid
insertion and a single-amino-acid substitution in dihydropteroate syn-
thase for the development of sulphonamide-resistant Neisseria
meningitidis. Microbiology. 2000;146(Pt 5):1151–6.
14. Dallas WS, Gowen JE, Ray PH, Cox MJ, Dev IK. Cloning, sequenc-
ing, and enhanced expression of the dihydropteroate synthase gene of
Escherichia coli MC4100. J Bacteriol. 1992;174:5961–70.
15. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE.
Sequence variation of the hydroxymethyldihydropterin pyrophospho-
kinase: dihydropteroate synthase gene in lines of the human malaria
parasite, Plasmodium falciparum, with differing resistance to sulfa-
doxine. Eur J Biochem. 1994;224:397–405.
16. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, et
al. Towards an understanding of the mechanism of pyrimethamine-
sulfadoxine resistance in Plasmodium falciparum: genotyping of
dihydrofolate reductase and dihydropteroate synthase of Kenyan par-
asites. Antimicrob Agents Chemother. 2000;44:991–6.
17. Volpe F, Dyer M, Scaife JG, Darby G, Stammers DK, Delves CJ. The
multifunctional folic acid synthesis fas gene of Pneumocystis carinii
appears to encode dihydropteroate synthase and hydroxymethyldihy-
dropterin pyrophosphokinase. Gene. 1992;112:213–8.
18. Lane BR, Ast JC, Hossler PA, Mindell DP, Bartlett MS, Smith JW, et
al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii.
J Infect Dis. 1997;175:482–5.
19. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith
JW, et al. Pneumocystis carinii mutations associated with sulfa and
sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12:873–8.
20. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD,
Lundgren B. Effects of mutations in Pneumocystis carinii dihy-
dropteroate synthase gene on outcome of AIDS-associated P. carinii
pneumonia. Lancet. 1999;354:1347–51.
21. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihy-
dropteroate synthase but not dihydrofolate reductase gene mutations
correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J
Infect Dis. 1999;180:1969–78.
22. Kazanjian P, Armstrong W, Hossler PA, Burman W, Richardson J,
Lee CH, et al. Pneumocystis carinii mutations are associated with
duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J
Infect Dis. 2000;182:551–7.
23. Huang L, Beard CB, Creasman J, Levy D, Duchin JS, Lee S, et al.
Sulfa or sulfone prophylaxis and geographic region predict mutations
in the Pneumocystis carinii dihydropteroate synthase gene. J Infect
Dis. 2000;182:1192–8.
24. Visconti E, Ortona E, Mencarini P, Margutti P, Marinaci S, Zolfo M,
et al. Mutations in dihydropteroate synthase gene of Pneumocystis
carinii in HIV patients with Pneumocystis carinii pneumonia. Int J
Antimicrob Agents. 2001;18:547–51.
25. Ma L, Kovacs JA, Cargnel A, Valerio A, Fantoni G, Atzori C.
Mutations in the dihydropteroate synthase gene of human-derived
Pneumocystis carinii isolates from Italy are infrequent but correlate
with prior sulfa prophylaxis. J Infect Dis. 2002;185:1530–2.
26. Ma L, Kovacs JA. Genetic analysis of multiple loci suggests that
mutations in the Pneumocystis carinii f. sp. hominis dihydropteroate
synthase gene arose independently in multiple strains. Antimicrob
Agents Chemother. 2001;45:3213–5.
27. Demanche C, Guillot J, Berthelemy M, Petitt T, Roux P, Wakefield
AE. Absence of mutations associated with sulfa resistance in
Pneumocystis carinii dihydropteroate synthase gene from non-human
primates. Med Mycol. 2002;40:315–8.
28. Kai M, Matsuoka M, Nakata N, Maeda S, Gidoh M, Maeda Y, et al.
Diaminodiphenylsulfone resistance of Mycobacterium leprae due to
mutations in the dihydropteroate synthase gene. FEMS Microbiol
Lett. 1999;177:231–5.
29. Costa MC, Helweg-Larsen J, Lundgren B, Antunes F, Matos O.
Mutations in the dihydropteroate synthase gene of Pneumocystis
jirovecii isolates from Portuguese patients with Pneumocystis pneu-
monia. Int J Antimicrob Agents. 2003;22:516–20.
30. Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille
J, et al. Association between a specific Pneumocystis jiroveci dihy-
dropteroate synthase mutation and failure of pyrimethamine/sulfa-
doxine prophylaxis in human immunodeficiency virus-positive and
-negative patients. J Infect Dis. 2003;188:1017–23.
31. Miller RF, Lindley AR, Ambrose HE, Malin AS, Wakefield AE.
Genotypes of Pneumocystis jiroveci isolates obtained in Harare,
Zimbabwe, and London, United Kingdom. Antimicrob Agents
Chemother. 2003;47:3979–81.
32. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et
al. Genetic variation in Pneumocystis carinii isolates from different
geographic regions: implications for transmission. Emerg Infect Dis.
2000;6:265–72.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 10, October 2004 1727
Pneumocystis DHPS Mutations and Sulfa Resistance
33. Huang L, Friedly J, Morris AM, Carter JL, Turner JR, Merrifield C,
et al. Pneumocystis carinii dihydropteroate synthase genotypes in
HIV-infected persons residing in San Francisco: possible implications
for disease transmission. J Eukaryot Microbiol. 2001;48:137S–8.
34. Latouche S, Lacube P, Maury E, Bolognini J, Develous M, Girard
PM, et al. Pneumocystis jirovecii dihydropteroate synthase genotypes
in French patients with pneumocystosis: a 1998–2001 prospective
study. Med Mycol. 2003;41:533–7.
35. Crothers K, Huang L, Morris A, Fox M, Groner G, Turner JR, et al.
Pneumocystis dihydropteroate synthase mutations in patients with
Pneumocystis pneumonia who are newly diagnosed with HIV infec-
tion. J Eukaryot Microbiol. 2003;50(Suppl):609–10.
36. Takahashi T, Endo T, Nakamura T, Sakashitat H, Kimurat K, Ohnishit
K, et al. Dihydrofolate reductase gene polymorphisms in
Pneumocystis carinii f. sp. hominis in Japan. J Med Microbiol.
2002;51:510–5.
37. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxa-
zole in Pneumocystis carinii infection and mutations in dihy-
dropteroate synthase gene. Lancet. 1998;351:1631–2.
38. Takahashi T, Hosoya N, Endo T, Nakamura T, Sakashita H, Kimura
K, et al. Relationship between mutations in dihydropteroate synthase
of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance
to sulfonamide therapy. J Clin Microbiol. 2000;38:3161–4.
39. Navin TR, Beard CB, Huang L, del Rio C, Lee S, Pieniazek NJ, et al.
Effect of mutations in Pneumocystis carinii dihydropteroate synthase
gene on outcome of P. carinii pneumonia in patients with HIV-1: a
prospective study. Lancet. 2001;358:545–9.
40. Huang L, Morris AM, Beard CB. Pneumocystis carinii dihy-
dropteroate synthase mutations and treatment with sulfa or sulfone
regimens: a proposal for standardized definitions for clinical evalua-
tion. J Eukaryot Microbiol. 2001;48:180S–1.
Address for correspondence: Laurence Huang, Positive Health Program,
Ward 84, San Francisco General Hospital, 995 Potrero Avenue, San
Francisco, CA 94110, USA; fax: 415-476-6953; email: lhuang@
php.ucsf.edu
1728 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 10, October 2004
PERSPECTIVES
Frank D. Duncan, Jr. (b. 1916),  Sisters of Mercy (1944). 
Watercolor on paper, 39.37 cm x 49.53 cm. U.S. Army Center of Military History, Washington, DC, USA
